143 related articles for article (PubMed ID: 24118850)
1. Effect of androgen deprivation therapy on muscle attenuation in men with prostate cancer.
Chang D; Joseph DJ; Ebert MA; Galvão DA; Taaffe DR; Denham JW; Newton RU; Spry NA
J Med Imaging Radiat Oncol; 2014 Apr; 58(2):223-8. PubMed ID: 24118850
[TBL] [Abstract][Full Text] [Related]
2. The clinical relevance of adiposity when assessing muscle health in men treated with androgen deprivation for prostate cancer.
Owen PJ; Daly RM; Dalla Via J; Mundell NL; Livingston PM; Rantalainen T; Fraser SF
J Cachexia Sarcopenia Muscle; 2019 Oct; 10(5):1036-1044. PubMed ID: 31067013
[TBL] [Abstract][Full Text] [Related]
3. Targeting muscle signaling pathways to minimize adverse effects of androgen deprivation.
de Rooy C; Grossmann M; Zajac JD; Cheung AS
Endocr Relat Cancer; 2016 Jan; 23(1):R15-26. PubMed ID: 26432470
[TBL] [Abstract][Full Text] [Related]
4. Muscle and bone effects of androgen deprivation therapy: current and emerging therapies.
Cheung AS; Zajac JD; Grossmann M
Endocr Relat Cancer; 2014 Oct; 21(5):R371-94. PubMed ID: 25056176
[TBL] [Abstract][Full Text] [Related]
5. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
Greenspan SL; Coates P; Sereika SM; Nelson JB; Trump DL; Resnick NM
J Clin Endocrinol Metab; 2005 Dec; 90(12):6410-7. PubMed ID: 16189261
[TBL] [Abstract][Full Text] [Related]
6. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.
Galvão DA; Spry NA; Taaffe DR; Newton RU; Stanley J; Shannon T; Rowling C; Prince R
BJU Int; 2008 Jul; 102(1):44-7. PubMed ID: 18336606
[TBL] [Abstract][Full Text] [Related]
7. Effects of strength training on muscle cellular outcomes in prostate cancer patients on androgen deprivation therapy.
Nilsen TS; Thorsen L; Fosså SD; Wiig M; Kirkegaard C; Skovlund E; Benestad HB; Raastad T
Scand J Med Sci Sports; 2016 Sep; 26(9):1026-35. PubMed ID: 26282343
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological inhibition of myostatin and changes in lean body mass and lower extremity muscle size in patients receiving androgen deprivation therapy for prostate cancer.
Padhi D; Higano CS; Shore ND; Sieber P; Rasmussen E; Smith MR
J Clin Endocrinol Metab; 2014 Oct; 99(10):E1967-75. PubMed ID: 24971661
[TBL] [Abstract][Full Text] [Related]
9. Comparing eccentric resistance exercise in prostate cancer survivors on and off hormone therapy: a pilot study.
Hansen PA; Dechet CB; Porucznik CA; LaStayo PC
PM R; 2009 Nov; 1(11):1019-24. PubMed ID: 19942188
[TBL] [Abstract][Full Text] [Related]
10. Does Use of Androgen Deprivation Therapy (ADT) in Men with Prostate Cancer Increase the Risk of Sarcopenia?
Owen PJ; Daly RM; Dalla Via J; Mundell NL; Livingston PM; Rantalainen T; Fraser SF
Calcif Tissue Int; 2019 Oct; 105(4):403-411. PubMed ID: 31317232
[TBL] [Abstract][Full Text] [Related]
11. Evidence for reduced neuromuscular function in men with a history of androgen deprivation therapy for prostate cancer.
Girard D; Marino FE; Cannon J
Clin Physiol Funct Imaging; 2014 May; 34(3):209-17. PubMed ID: 24119067
[TBL] [Abstract][Full Text] [Related]
12. Androgen deprivation causes selective deficits in the biomechanical leg muscle function of men during walking: a prospective case-control study.
Cheung AS; Gray H; Schache AG; Hoermann R; Lim Joon D; Zajac JD; Pandy MG; Grossmann M
J Cachexia Sarcopenia Muscle; 2017 Feb; 8(1):102-112. PubMed ID: 27897410
[TBL] [Abstract][Full Text] [Related]
13. Quality of life in prostate cancer patients taking androgen deprivation therapy.
Dacal K; Sereika SM; Greenspan SL
J Am Geriatr Soc; 2006 Jan; 54(1):85-90. PubMed ID: 16420202
[TBL] [Abstract][Full Text] [Related]
14. Osteoporosis and prostate cancer: a cross-sectional study of Danish men with prostate cancer before androgen deprivation therapy.
Poulsen MH; Frost M; Abrahamsen B; Brixen K; Walter S
Scand J Urol; 2014 Aug; 48(4):350-5. PubMed ID: 24548220
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and predictive factors for the development of de novo psychiatric illness in patients receiving androgen deprivation therapy for prostate cancer.
DiBlasio CJ; Hammett J; Malcolm JB; Judge BA; Womack JH; Kincade MC; Ogles ML; Mancini JG; Patterson AL; Wake RW; Derweesh IH
Can J Urol; 2008 Oct; 15(5):4249-56; discussion 4256. PubMed ID: 18814813
[TBL] [Abstract][Full Text] [Related]
16. Actin alpha cardiac muscle 1 gene expression is upregulated in the skeletal muscle of men undergoing androgen deprivation therapy for prostate cancer.
Cheung AS; de Rooy C; Levinger I; Rana K; Clarke MV; How JM; Garnham A; McLean C; Zajac JD; Davey RA; Grossmann M
J Steroid Biochem Mol Biol; 2017 Nov; 174():56-64. PubMed ID: 28756295
[TBL] [Abstract][Full Text] [Related]
17. Attenuation of Resting but Not Load-Mediated Protein Synthesis in Prostate Cancer Patients on Androgen Deprivation.
Hanson ED; Nelson AR; West DW; Violet JA; O'Keefe L; Phillips SM; Hayes A
J Clin Endocrinol Metab; 2017 Mar; 102(3):1076-1083. PubMed ID: 28359098
[TBL] [Abstract][Full Text] [Related]
18. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.
Diamond TH; Higano CS; Smith MR; Guise TA; Singer FR
Cancer; 2004 Mar; 100(5):892-9. PubMed ID: 14983482
[TBL] [Abstract][Full Text] [Related]
19. A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy.
Nobes JP; Langley SE; Klopper T; Russell-Jones D; Laing RW
BJU Int; 2012 May; 109(10):1495-502. PubMed ID: 21933330
[TBL] [Abstract][Full Text] [Related]
20. Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial.
Cormie P; Galvão DA; Spry N; Joseph D; Chee R; Taaffe DR; Chambers SK; Newton RU
BJU Int; 2015 Feb; 115(2):256-66. PubMed ID: 24467669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
